{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:24Z","timestamp":1791559464849,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002243"],"award-info":[{"award-number":["UL1 TR002243"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30 CA68485-19"],"award-info":[{"award-number":["5P30 CA68485-19"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shared Instrumentation","award":["S10 OD023475-01A1"],"award-info":[{"award-number":["S10 OD023475-01A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Epstein-Barr virus\u2013positive large B-cell lymphoma (EBV+ LBCL) is a heterogeneous group of diseases that may resemble classic Hodgkin lymphoma (CHL) both morphologically and immunophenotypically. However, these diseases are treated with different therapies and carry distinct prognoses. We examined CD200 expression by immunohistochemistry in EBV+ LBCL and evaluated its diagnostic utility in the differential diagnosis with CHL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>CD200 immunohistochemistry was performed on archival material from 20 cases of CHL (11 EBV+, 9 EBV\u2212), 11 cases of EBV+ LBCL, and 10 cases of diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS). Staining pattern and intensity (0-3+ scale) were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CD200 positivity was seen in Reed-Sternberg cells in 19 (95%) of 20 cases of CHL, predominantly in a strong (3+, 15\/19) and diffuse (&amp;gt;50% of cells, 17\/19) pattern. In contrast, CD200 was negative in 8 (73%) of 11 cases of EBV+ LBCL; the 3 positive cases showed 1 to 2+ staining in less than 50% of lesional cells. All cases of DLBCL NOS were negative for CD200.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CD200 may be a useful immunophenotypic marker in differentiating EBV+ LBCL from CHL, with negative to partial\/weak staining favoring a diagnosis of EBV+ LBCL and strong diffuse staining favoring a diagnosis of CHL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad053","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T19:32:09Z","timestamp":1685043129000},"page":"284-291","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostic Utility of CD200 Immunohistochemistry in Distinguishing EBV-Positive Large B-Cell Lymphoma From Classic Hodgkin Lymphoma"],"prefix":"10.1093","volume":"160","author":[{"given":"Christopher","family":"Batuello","sequence":"first","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center , Nashville, TN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily F","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center , Nashville, TN , US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"2023090111552773700_CIT0001","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Swerdlow","year":"2017","edition":"4"},{"key":"2023090111552773700_CIT0002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am J Surg Pathol."},{"key":"2023090111552773700_CIT0003","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res."},{"key":"2023090111552773700_CIT0004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/annonc\/mdu556","article-title":"EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity","volume":"26","author":"Hong","year":"2015","journal-title":"Ann Oncol."},{"key":"2023090111552773700_CIT0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.humpath.2015.01.011","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly","volume":"46","author":"Uccini","year":"2015","journal-title":"Hum Pathol."},{"key":"2023090111552773700_CIT0006","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood."},{"key":"2023090111552773700_CIT0007","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","article-title":"Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified","volume":"5","author":"Bourbon","year":"2021","journal-title":"Blood Adv."},{"key":"2023090111552773700_CIT0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br J Haematol."},{"key":"2023090111552773700_CIT0009","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am J Hematol."},{"key":"2023090111552773700_CIT0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1349-7006.2008.00813.x","article-title":"Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease","volume":"99","author":"Shimoyama","year":"2008","journal-title":"Cancer Sci."},{"key":"2023090111552773700_CIT0011","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer\u2014a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"2023090111552773700_CIT0012","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/his.13100","article-title":"Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases","volume":"70","author":"Elsayed","year":"2017","journal-title":"Histopathology."},{"key":"2023090111552773700_CIT0013","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1309\/AJCP38XRRUGSQOVC","article-title":"CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms","volume":"134","author":"Dorfman","year":"2010","journal-title":"Am J Clin Pathol."},{"key":"2023090111552773700_CIT0014","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/modpathol.2012.129","article-title":"Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers","volume":"25","author":"Dorfman","year":"2012","journal-title":"Mod Pathol."},{"key":"2023090111552773700_CIT0015","doi-asserted-by":"crossref","first-page":"151585","DOI":"10.1016\/j.anndiagpath.2020.151585","article-title":"Increased CD200 expression in post-transplant lymphoproliferative disorders correlates with an increased frequency of FoxP3(+) regulatory T cells","volume":"48","author":"Vaughan","year":"2020","journal-title":"Ann Diagn Pathol."},{"key":"2023090111552773700_CIT0016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1074-7613(00)00023-6","article-title":"Lymphoid\/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function","volume":"13","author":"Wright","year":"2000","journal-title":"Immunity."},{"key":"2023090111552773700_CIT0017","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1126\/science.290.5497.1768","article-title":"Down-regulation of the macrophage lineage through interaction with OX2 (CD200)","volume":"290","author":"Hoek","year":"2000","journal-title":"Science."},{"issue":"3","key":"2023090111552773700_CIT0018","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.4049\/jimmunol.163.3.1654","article-title":"An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival","volume":"163","author":"Gorczynski","year":"1999","journal-title":"J Immunol"},{"key":"2023090111552773700_CIT0019","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/leu.2012.75","article-title":"Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells","volume":"26","author":"Coles","year":"2012","journal-title":"Leukemia."},{"key":"2023090111552773700_CIT0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/leu.2011.1","article-title":"CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia","volume":"25","author":"Coles","year":"2011","journal-title":"Leukemia."},{"issue":"9","key":"2023090111552773700_CIT0021","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/01.TP.0000152118.51622.F9","article-title":"Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R","volume":"79","author":"Gorczynski","year":"2005","journal-title":"Transplantation"},{"key":"2023090111552773700_CIT0022","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood."},{"key":"2023090111552773700_CIT0023","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","article-title":"CD200 as a prognostic factor in acute myeloid leukaemia","volume":"21","author":"Tonks","year":"2007","journal-title":"Leukemia."},{"key":"2023090111552773700_CIT0024","doi-asserted-by":"crossref","first-page":"104597","DOI":"10.1016\/j.yexmp.2020.104597","article-title":"Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia","volume":"118","author":"Kandeel","year":"2021","journal-title":"Exp Mol Pathol."},{"key":"2023090111552773700_CIT0025","doi-asserted-by":"crossref","first-page":"584427","DOI":"10.3389\/fonc.2020.584427","article-title":"CD200 and chronic lymphocytic leukemia: biological and clinical relevance","volume":"10","author":"D\u2019Arena","year":"2020","journal-title":"Front Oncol."},{"key":"2023090111552773700_CIT0026","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s40425-019-0710-1","article-title":"Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200","volume":"7","author":"Mahadevan","year":"2019","journal-title":"J ImmunoTher Cancer."},{"key":"2023090111552773700_CIT0027","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/3\/284\/51293306\/aqad053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/3\/284\/51293306\/aqad053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:58:19Z","timestamp":1693569499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/3\/284\/7179726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad053","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,5,25]]}}}